Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (272)	8/30/1999 11:19:00 AM
From: DENNIS TULLY	Read Replies (2) \| Respond to of 666

This is now the best buying opportunity I have seen. IMO this will be back to 30 THIS WEEK!

To: Vector1 who wrote (272)	8/30/1999 1:50:00 PM
From: RCMac	Respond to of 666

From Reuters story today on FDA request: >>Eric Ende, a pharmaceuticals analyst for Lehman Brothers, said the FDA request could delay the launch of Bexxar by three and a half months and could delay Coulter's first quarterly profit. . . . . . ''We believe that we can respond quickly to these requests and will work closely with our partners and the FDA toward an expeditious acceptance of our application,'' Coulter Chief Executive Michael Bigham said. . . . . . Lehman Brothers' Ende said Coulter officials told him this morning that they expect to resubmit the marketing application to the FDA by mid-October and expect to see Bexxar launched in the United States by next April. As a result of the delayed launch, Ende said, he is cutting his 2000 sales forecast for Bexxar to $66 million from $123 million, and reducing his 2001 forecast to $137 million from $199 million. ''I now don't expect the company to become profitable until 2002, whereas initially I expected Coulter to start making money in 2001,'' the analyst added. He said Coulter officials had told him the FDA had requested changes in seven areas. ''None of them appear serious on the surface, but when you add them up they create more risk,'' he said. ''They make you wonder if the FDA later will want yet more data.'' Among the items requested by the FDA is more data on how radiation from Bexxar affected organs in the body, he said. ''Coulter claims to already have the data,'' Ende added. <<